- Home
- SKIN vs DTIL Comparison
SKIN vs DTIL Comparison
Compare SKIN & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | DTIL |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.9M | 128.8M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SKIN | DTIL |
|---|---|---|
| Price | $0.82 | $6.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.03 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 750.6K | 317.3K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $300,790,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $1.24 | N/A |
| Revenue Next Year | $4.73 | $34.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $3.53 |
| 52 Week High | $2.69 | $8.82 |
Technical Indicators
Market Signals| Indicator | SKIN | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 59.75 |
| Support Level | N/A | $3.96 |
| Resistance Level | $1.61 | $7.59 |
| Average True Range (ATR) | 0.10 | 0.58 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 2.62 | 44.61 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.